UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Blood marker linked to Alzheimer’s also found in systemic amyloidosis

A certain blood protein regarded as an early indicator of Alzheimer's disease also appears to play a role in other disorders. Researchers at DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen have found that elevated levels of phosphorylated tau protein (pTau) also occur in two lesser-known conditions that primarily affect the heart and kidneys. These findings open up new perspectives for improved diagnostics and were published this week in the journal "Nature Medicine".

News Date

Alnylam's Helios B Trial Explained: A Plain Language Summary

What is this summary about?This summary explains the results of the HELIOS-B study that assessedvutrisiran treatment in transthyretin amyloidosis with cardiomyopathy(ATTR-CM). In ATTR-CM, a protein called transthyretin accumulates in clumpscalled amyloid in different parts of the body, such as the heart and nerves,causing damage. In the heart, this decreases functioning and leads to heartfailure and therefore more frequent hospital visits and a greater risk of dying.Vutrisiran lowers the amount of transthyretin in the blood.

A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils

Immunoglobulin light chain (LC) amyloidosis (AL) is one of the most common types of systemic amyloidosis but there is no reliable in vivo model for better understanding this disease. Here, we develop a transgenic mouse model producing a human AL LC. We show that the soluble full length LC is not toxic but a single injection of pre-formed amyloid fibrils or an unstable fragment of the LC leads to systemic amyloid deposits associated with early cardiac dysfunction. AL fibrils in mice are highly similar to that of human, arguing for a conserved mechanism of amyloid fibrils formation.

News Date

Amyloidosis Centre Success Story

Watch the success stories by Professor Marianna Fontana and Christine Chiti from the National Amyloidosis Centre Royal Free Hospital in London. 

Amyloidosis is a complex disease encompassing various subtypes. It places a significant burden on patients and healthcare systems worldwide. 

Amyloidosis is a complex disease encompassing various subtypes. It places a significant burden on patients and healthcare systems worldwide. 

Contemporary Strategies: Diagnosing ATTR Amyloidosis

Early diagnosis and intervention for transthyretin amyloidosis (ATTR) is critical, yet does not occur, typically as a consequence of the rarity and heterogeneity of the disease and limited awareness on the part of clinicians. Therapeutic options are limited, but there are new and emerging agents and emerging indications with which clinicians may not be familiar. Access to specialized care centers is limited for many patients, leading to suboptimal management and disease monitoring.